TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03330106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Pevonedistat intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Pevonedistat intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Pevonedistat intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel intravenous infusion.
Study: NCT01416506

Intervention type: OTHER
Intervention: No Drug
Description: It's a surveillance
Study: NCT03568760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semantic feature analysis
Description: Confrontation naming training and training in doing circumlocutions

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Comprehension training
Description: Reading and hearing comprehension
Study: NCT02837016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable biofeedback

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Treatment
Description: group-based relaxation treatment based on mindfulness meditation principles

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Treatment
Description: group-based relaxation treatment based on mindfulness meditation principles
Study: NCT04172506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK105
Description: Anti-PD-1 antibody
Study: NCT02174120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Study: NCT04180475

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedRem application
Description: Medication adherence smartwatch application
Study: NCT02174120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etomidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etomidate
Study: NCT04044235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP Cohort
Description: AGYW who are eligible for PrEP will be educated about the risk and benefits. For AGYW (aged 18-24 years) who consent to PrEP, an ART provider (nurse or clinician) certified by the MOH will provide PrEP (package of disoproxil fumarate/emtricitabine (Truvada)) on the same day that the client is determined eligible. Peer navigators will ensure linkage to facilities for follow-up care. The initial follow-up visit will occur one month from PrEP initiation to ensure that the client is tolerating the regimen and to answer any questions, with three-month follow-up visits thereafter.
Study: NCT03748875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based relapse prevention
Description: mindfulness-based relapse prevention, 8 weeks
Study: NCT04068220

Intervention type: OTHER
Group type: OTHER
Intervention: intraoperative FVEPs monitoring
Description: During the surgery, a pair of goggles (similar to the swimming goggles) will be placed on patient's closed eyes. The goggles equipped with red LEDs will apply no pressure or minimal pressure on patient's closed eyes. Patient's left eye then right eye will be stimulated with flashing red light emitted by the goggles. Two subdermal needle electrodes will be placed under the skin behind patient's ears, and one subdermal needle electrode will be placed under the skin above the bridge of patient's nose. The two electrodes placed behind patient's ears, will record intraoperative flash visual evoked potentials (FVEPs) resulted from red light stimulation of patient's visual pathway through the eyes and the electrode above the bridge of the nose will record, at the same time, the activity of each eye's retina.
Study: NCT03773081

Intervention type: DEVICE
Group type: OTHER
Intervention: Implantation of the Magmaris scaffold
Description: Subjects will undergo a PCI for the implantation of the Magmaris scaffold in accordance with the standard of care and standard hospital practice. Maximum of one single ACS-causing de novo lesions in one separate major epicardial vessels is allowed.
Study: NCT00935467

Intervention type: DRUG
Group type: OTHER
Intervention: Saxagliptin
Description: Tablets, oral, 2.5 mg, twice daily, 7 days
Study: NCT04829864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEP
Description: The program is offered by two facilitators to groups of three to seven women, in-person or online. The program is divided in three phases entitles Becoming a mother; A look at my own history and Looking ahead. The first phase aims to explore and normalize the emotions experienced by the participants in the course of their pregnancy and to support the use of healthy emotion regulation strategies. The second phase aims to support mentalization of trauma, by discussing the nature of trauma and its impact; by validating participants' feelings as understandable responses to trauma; by supporting a reflection on positive and harsh experiences with significant others and the ways both types of experiences influenced participants' mental states; and identifying how participants coped with trauma. In the last phase, discussions focus on participants' needs and strengths, on available resources to support resilience and envision positive and challenging moments with the child.
Study: NCT02187185

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sonicare/Elite-Flexcare Toothbrush
Description: Philips Oral Healthcare product - battery powered menchanic toothbrush with nylon bristles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Toothbrush
Description: traditional (non-mechanical) toothbrush with nylon bristles and plastic handle
Study: NCT01073553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin capsules (Optocef, BAYO5448 )
Description: Single dose of 500 mg (One 500 mg capsule)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin capsules (Keflex)
Description: Single dose of 500 mg (Two 250 mg capsules)
Study: NCT03140553

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCH (docetaxel/carboplatin/trastuzumab) versus EC-TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab)
Description: TCH (docetaxel/carboplatin/trastuzumab) versus EC followed by TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab) as Neoadjuvant Treatment for HER2-Positive Breast Cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCH (docetaxel/carboplatin/trastuzumab) versus EC-TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab)
Description: TCH (docetaxel/carboplatin/trastuzumab) versus EC followed by TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab) as Neoadjuvant Treatment for HER2-Positive Breast Cancer
Study: NCT02056782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dociparstat sodium
Description: The following induction regimen was administered:~* Cytarabine (100 mg/m2/day) via continuous intravenous (IV) infusion 24 hours daily for 7 days.~* Idarubicin (12 mg/m2/day) IV on Days 1, 2, and 3.~* Dociparstat (4 mg/kg) given over 5 minutes IV, immediately after the idarubicin dose on Day 1, followed by a continuous IV infusion (0.25 mg/kg/hr for 24 hours daily) for a total of 7 days.
Study: NCT02224040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftriaxone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftriaxone and azithromycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin and cefixime
Study: NCT02689388

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: Use of femoral nerve block as part of general anesthesia
Study: NCT02710422

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amniotic Membrane Placement
Description: Amniotic membranes will be placed over the neurovascular bundle after extirpative RARP, and before the urethrovesical anastomosis. The membrane will cut into two longitudinal pieces and it will be placed over each neurovascular bundle separately.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EPIC 26
Description: Participants will receive EPIC 26 psychosocial questionnaire at baseline, and post-RARP at protocol-defined intervals.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: EPIC 26
Description: Participants will receive EPIC 26 psychosocial questionnaire at baseline, and post-RARP at protocol-defined intervals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSA Measurement
Description: Measurement of serum PSA levels every three months (+ 1 month) for first year post surgery, and then annually for 5 years.

Intervention type: OTHER
Group type: OTHER
Intervention: PSA Measurement
Description: Measurement of serum PSA levels every three months (+ 1 month) for first year post surgery, and then annually for 5 years.
Study: NCT03812549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Patients will receive treatment with Sintilimab 200mg every 3 weeks for a maximum of 24 months.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Radiation treatment utilized in this trial consists of SBRT with a standard doses to 30 Gy/3f

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Dose Radiotherapy
Description: LDRT at dose escalation levels: 2 Gy/1f, 4 Gy/2f, 10 Gy/5f with conventional external beam radiation.
Study: NCT03715504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-3654
Description: oral PIM inhibitor
Study: NCT03854682

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency microtenotomy
Description: A longitudinal incision of about 3 cm will be made over the most tender part of the foot taking care to avoid the weight bearing part of the sole, and the tissues dissected down to the affected plantar fascia. After initiating sterile isotonic saline flow of 1 drop every 1-2 s from a line connected to the RF system, the TOPAZ tip will be placed onto the fascia and the micro debridements carried out in a grid like pattern on and throughout the symptomatic fascia area. After debridement, the wound will be irrigated with copious amounts of normal saline solution and closed in layers. A local anaesthetic will be injected into the skin and subcutaneous tissues around the wound and standard wound dressings will be applied
Study: NCT02433483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given by either intrathecal (IT) or intravenous (IV) route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Triples
Description: given IT.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPC-A
Description: Given IV.
Study: NCT02037698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-PCI coronary CT scan
Description: Coronary CT scan before CTO PCI
Study: NCT02198742

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Miller blade
Description: To participate in the study the subjects must have \>500 intubations with the miller blade.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Truview PCD
Description: Subjects were given a quick guide of the Truview PCD supplied by the manufacturer with step by step instructions for use. They were also given time to practice with the device on a normal model until they felt comfortable.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope Cobolt
Description: Subjects were required to watch a instructional video provided by the manufacturer. Subjects were then allowed to practice on a normal model until they felt comfortable before beginning the study. There is no placebo group, and each subject wil be his or her own control.
Study: NCT03053323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: The lifestyle intervention consists of three components: nutrition, physical activity, and other areas of wellness. The intervention is administered individually each week for 10 weeks and is tailored for women with a history of depression who are in the first trimester of pregnancy or trying to conceive.
Study: NCT02710422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual History Inventory for Men
Description: SHIM psychosocial questionnaire administered at baseline, and post-RARP at protocol-defined intervals.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sexual History Inventory for Men
Description: SHIM psychosocial questionnaire administered at baseline, and post-RARP at protocol-defined intervals.
Study: NCT02552199

Intervention type: OTHER
Intervention: gravimetric

Intervention type: OTHER
Intervention: gravimetric
Study: NCT01760707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Study: NCT00754819

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: 1mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule daily
Study: NCT04610840

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Puncture of the caliceal system
Description: Puncture of the caliceal system under ultrasound/Xray control

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Puncture of the caliceal system
Description: Puncture of the caliceal system under ultrasound/Xray control
Study: NCT01806545

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SRM003
Description: One time implant (2 SRM003 pieces) on surgery day.

Intervention type: OTHER
Group type: OTHER
Intervention: Participating Site's standard practice
Description: Subjects will receive sites' standard practice treatment during the surgical procedure.
Study: NCT02116907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007
Description: 14C-labeled perampanel dissolved in ethanol and administered using a capsule formulation in a single dose, one day
Study: NCT00281528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007 (Abraxane)
Description: 30 minute infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007 (Abraxane)
Description: 30 minute infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007 (Abraxane)
Description: 30 minute infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: infusions
Study: NCT02107976

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: 400 IU per day after discharge, for a minimum of 8 weeks between Stage 1 and Stage 2

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: 400 IU per day after discharge, for a minimum of 8 weeks between Stage 1 and Stage 2
Study: NCT04590430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HFB30132A
Description: Participants randomized to HFB30132A will be administered dose 1 in cohort 1. Participants in Cohort 2 and 3 will receive HFB30132A doses 2 and 3, respectively.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to placebo will receive the same volume of solution as participants on active treatment.
Study: NCT02709460

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral occlusion
Description: Lateral occlusion close to the internal Iliac artery
Study: NCT02107976

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 500mg twice a day after discharge, for a minimum of 8 weeks between Stage 1 and Stage 2

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 500mg twice a day after discharge, for a minimum of 8 weeks between Stage 1 and Stage 2
Study: NCT03502590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IGEL Laryngeal mask
Description: Insertion of an IGEL device in anaesthetised patients
Study: NCT03495960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Rituximab is given 375 mg/m2 as standard infusion at days -6, 1, 15 \& 29. Rituximab on day -6 will be delivered only during the first course; it will be delivered between day -6 and day 0 according to clinical requirements and patient's conditions. Some patients would need for a fast chemotherapy starting.~PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Rituximab is given 375 mg/m2 in 4 weekly doses, starting on day 2 of radiotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Rituximab is given 375 mg/m2 as standard infusion at days -6, 1, 15 \& 29. Rituximab on day -6 will be delivered only during the first course; it will be delivered between day -6 and day 0 according to clinical requirements and patient's conditions. Some patients would need for a fast chemotherapy starting.~PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Rituximab is given 375 mg/m2 in 4 weekly doses, starting on day 2 of radiotherapy.

Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab
Description: PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Rituximab is given 375 mg/m2 as standard infusion at days -6, 1, 15 \& 29. Rituximab on day -6 will be delivered only during the first course; it will be delivered between day -6 and day 0 according to clinical requirements and patient's conditions. Some patients would need for a fast chemotherapy starting.~PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Rituximab is given 375 mg/m2 in 4 weekly doses, starting on day 2 of radiotherapy.
Study: NCT02709460

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical occlusion
Description: Cervical occlusion of the uterine artery
Study: NCT02903225

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Rehabilitation
Description: All patients included in this group attended a supervised exercise training program. A cardiologist supervised the hole training sessions. Blood pressure, pulse rate, oxygen saturation, and body weight were measured in each session. The modified Borg scale was used to measure the perceived exercise intensity
Study: NCT01601106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liposomal prednisolone
Description: Two weekly dosages with 150 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: liposomal prednisolone
Description: Two weekly dosages with 150 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02957422

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1% Milk
Description: 1.5 gallons of 1% milk will be delivered to the participant's home weekly. Participants will be asked to drink 3 cups per day for 3 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will continue on their regular low dairy diet of ≤1.5 dairy serving/day.
Study: NCT02272491

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZrO2 (Straumann CARES)
Description: 1. Straumann CARES Variobase Abutment RN~2. Straumann CARES Full Contour Zerion HT The monolithic zircona crown (2) will be bonded to the titanium base (1)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFM crown (Straumann Gold)
Description: Porcelain-fused-to-metal crown consisting of a gold abutment, a gold core, and veneering ceramic
Study: NCT01508650

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care control group

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation intervention
Description: Multi-domain rehabilitation intervention
Study: NCT04165434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concurrent Training
Description: Strength training and interval aerobic training in the same training session
Study: NCT03258151

Intervention type: GENETIC
Intervention: detection of genotype
Description: detection of genotype by next generation sequencing

Intervention type: GENETIC
Intervention: detection of genotype
Description: detection of genotype by next generation sequencing
Study: NCT03095014

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cesarean Myomectomy
Description: Myomectomy was done during Cesarean section

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean section
Description: Cesarean delivery
Study: NCT01851616

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 25g of glucose in 200ml tap water, given orally (plus 50 mg 13C-sodium acetate)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)
Study: NCT01463878

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glycerna
Description: Diabetes specific formula

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Jevity - Control Diet
Description: Control Diet
Study: NCT04376372

Intervention type: DIAGNOSTIC_TEST
Intervention: Functional testing, Magnetic resonance imaging, Electromyography
Description: Electromyography only for cases (F-Lefthanders), not for controls (TD-lefthanders)

Intervention type: DIAGNOSTIC_TEST
Intervention: Functional testing, Magnetic resonance imaging, Electromyography
Description: Electromyography only for cases (F-Lefthanders), not for controls (TD-lefthanders)